|Bid||2.7900 x 0|
|Ask||2.7950 x 0|
|Day's Range||2.7900 - 2.7950|
|52 Week Range||2.4000 - 6.2500|
|Beta (3Y Monthly)||1.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.15|
September 6, 2019Announcement no. 18 Updated Financial calendar for 2019 and Financial calendar for 2020 DateDescriptionNovember 21, 2019Interim report – for the nine-month.
Today, the Board of Directors of BioPorto A/S ("BioPorto") (BIOPOR.CO) has decided to exercise part of the current authorization by issuing 1,500,000 new warrants to certain key employees in the Company’s U.S. organization. The warrants are issued in accordance with the company's Remuneration policy and guidelines for incentive-based remuneration and the authorization in section 18 of the Articles of Association.
August 15, 2019Announcement no. 16 BioPorto A/S - Extraordinary General MeetingToday, BioPorto A/S held an extraordinary general meeting where Christopher Lindop and.
August 15, 2019 Announcement no. 15 Q2 2019 Report Highlights Additional Information request from FDA on the pediatric application for The NGAL Test™ postpones clearance In.
While BioPorto A/S (CPH:BIOPOR) shareholders are probably generally happy, the stock hasn't had particularly good run...
BioPorto A/S (“BioPorto”) announces today that the company has received an Additional Information (“AI”) request letter from the U.S. Food and Drug Administration (“FDA”) regarding the application for regulatory clearance of the NGAL Test for risk assessment of acute kidney injury (“AKI”) in critical ill patients under the age of 22. The AI request primarily concerns the clinical study data and collection of retrospective samples, which has been collected in close collaboration with leading kidney specialists at Cincinnati Children’s Hospital in U.S. BioPorto has reviewed FDA’s AI request and concluded, that the existing clinical studies and data do not constitute sufficient basis to proceed with the current application.
July 12, 2019 Announcement no. 13 NOTICE CONVENING THE EXTRAORDINARY GENERAL MEETING The Board of Directors hereby convenes an Extraordinary General Meeting of BioPorto A.
BioPorto A/S Managers' Transactions June 28, 2019Company announcement no. 11 Managers’ transactions BioPorto A/S has received notification pursuant to article 19 of.
The Board of Directors of BioPorto A/S (“BioPorto”) decided on June 17, 2019 to partially exercise the authorization in article 16b of the company’s Articles of Association to issue 9,256,577 new shares in a private placement to a limited number of domestic and international shareholders, institutional and financial investors (company announcement no. 8 of June 17, 2019). BioPorto has now received the full subscription amount and the capital increase of in total nominally DKK 9,256,577 has been registered and completed with the Danish Business Authority. BioPorto’s gross proceeds from the issue will amount to DKK 36,748,610 equivalent to USD 5.5 million. The aggregate net proceeds are expected to amount to DKK 36,013,610 after deduction of costs. The new shares are equivalent to 5.59% of BioPorto’s registered share capital prior to the share capital increase and is exempt from the requirement to publish a prospectus.
Today, BioPorto A/S CPH:BIOPOR (“BioPorto”) announces the appointment of Christopher Bird as Chief Medical Officer (CMO) and newest member of BioPorto’s global leadership team. Christopher joins BioPorto from Roche Diagnostics Corp., where he most recently headed the North American Medical and Scientific Affairs organization with responsibility for all clinical education, non-registrational study management and field support. Chris has a bachelor’s degree in physiology from Brigham Young University, a master’s degree in biochemistry and molecular biology from University of California Los Angeles, and a DPhil in molecular immunology from Oxford University as an Abraham Scholar.
With reference to company announcement no. 8 of 17 June 2019, the Board of Directors of BioPorto A/S (“BioPorto”) can announce that the private placement described therein, comprising 9,256,577 new shares, has been fully subscribed for. The aggregate subscription price for the new shares, DKK 36,748,610, is to be paid in prior to the end of June 2019, and BioPorto thus expects to complete the share capital increase and issue the new shares in early July 2019. BioPorto has its headquarters in Hellerup, Denmark and is listed on the Nasdaq Copenhagen stock exchange.
Today, BioPorto A/S will initiate a private placement of 9,256,577 new shares to select domestic and international shareholders, institutional and financial investors. The Board of Directors has received binding advanced subscription commitments for the full offering, which will be made at market price without pre-emptive subscription rights for existing shareholders.
May 15, 2019Announcement no. 7 BioPorto Submits Pediatric Application to FDA for The NGAL Test™ Under Breakthrough Designation First test focused on risk.
Also in accordance to plan, BioPorto has in first quarter 2019 commenced the enrollment of additional patients in the clinical study for the FDA application for The NGAL Test for use in adults. The final application for this indication is expected to be submitted to the FDA later in 2019, with clearance - subject to timing of the FDA process - expected in the second half of 2019. In the first quarter of 2019 BioPorto has expanded its U.S. sales force to broaden its customer base among cardiac and kidney transplant centers and accelerate the momentum of awareness building of the NGAL biomarker and of Research Use Only (RUO) sales.
Today, BioPorto A/S CPH: BIOPOR (“BioPorto”) announces the appointment of Amy Winslow as President for the US subsidiary, BioPorto Diagnostics, Inc. Amy Winslow, a highly experienced diagnostic executive, will be responsible for building and leading the US organization as BioPorto prepares to launch The NGAL Test™ for clinical use following expected clearance by the U.S. Food and Drug Administration (“FDA”) later this year. Amy Winslow joins BioPorto Diagnostics in April 2019 having most recently served as President and CEO of Magellan Diagnostics, a Boston-based point-of-care diagnostics company.
If you're interested in BioPorto A/S (CPH:BIOPOR), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. Volatility is considered to be a me...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! BioPorto A/S's (CPH:BIOPOR): BioPorto A/S, an in-vitro diagnostics company, providesRead More...
The Board of Directors proposes that the Board's report on the Company’s activities for the past year be noted. The Board of Directors proposes that the audited annual report for 2018, including the proposal that this year’s results be brought forward, is approved.
February 22, 2019 Announcement no. 2 Annual Report 2018 Full speed ahead Highlights from the Annual Report 2018 Revenue growth of 80% from sales of The NGAL Test™ in.
January 8, 2019 Announcement no. 1 Corrected Financial Calendar 2019 DATE 2019DESCRIPTIONJanuary 25, 2019Quiet Period prior to the Annual Report begins (4.
BioPorto A/S (CPH:BIOPOR), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is BIOPOR will Read More...
In accordance with the company's guidelines relating to incentive remuneration and the authorization in Section 18 of the Articles of Association, the Board of Directors of BioPorto A/S ("BioPorto") (BIOPOR.CO) has decided to issue 2,500,000 new warrants to certain members of BioPorto’s Corporate Management. Each warrant grants the holder the right to subscribe for one share in the company. Conditions for exercising of all warrants apply in case the Company achieve FDA approval of The NGAL Test™ before December 31, 2019, if 50 new hospital customer sites in the USA are achieved no longer than 12 months after the approval, and if the company achieve NGAL revenue growth of 100 % (in local currency) in the USA ) in the 12 months after the approval compared to the 12 months before the approval.
November 28, 2018Announcement no. 24 Share Capital and Votes Pursuant to section 32 of the Danish Capital Markets Act, it is hereby announced, that BioPorto A/S’ total share.